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A B S T R A C T
Despite recent advances in iron chelation therapy, excess iron deposition in pituitary gonadotropic cells
remains one of the major problems in thalassemic patients. Hypogonadism, mostly hypogonadotropic
hypogonadism, is usually detected during puberty. Early diagnosis and treatment are crucial for normal
pubertal development and to reduce the complications of hypogonadism. The risks and beneﬁts of hor-
monal replacement therapy, especially regarding the thromboembolic event, remain a challenge for providers
caring for thalassemic patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Thalassemia refers to a group of inherited diseases character-
ized by decreased or absent synthesis of normal globin chains [1].
The direct consequence is an imbalance of the alpha and beta globin
chain synthesis that results in anemia from ineffective erythropoi-
esis and hemolysis. The term thalassemia major refers to the severe
form that is often associated with life-long transfusion dependent
anemia.
Hypogonadism is the most frequently reported endocrine
complication, affecting 70–80% of thalassemia major patients. Hy-
pogonadism is likely to be caused by iron deposits in the gonads,
pituitary gland or both. However, hypogonadotropic hypogonad-
ism resulting from iron deposition in the pituitary gonadotrope is
more commonly found. Gonadal iron deposition in ovaries or testes
occurs less frequently, as the majority of amenorrheic women can
still ovulate after hormonal treatment.
In normal individuals, iron homeostasis is controlled mainly by
iron absorption, not excretion. Lacking adequate excretory mecha-
nisms, thalassemic patients receiving a blood transfusion (usually
1mgof iron per 1mL of blood) inevitably experience signiﬁcant iron
overload. Normally, iron is bound to transferrin and transported to
bone marrow and tissue, where transferrin receptor takes up iron
and stores it as ferritin. Transferrin saturation is usually main-
tained at 10–50%, and less than 1% of total body iron is found in the
blood. As a consequence of iron overload in thalassemic patients,
either from blood transfusion or excessive iron absorption, trans-
ferrin is fully saturatedandnon-transferrin-bound iron (NTBI) is found
excessively in the blood. Instead of using the transferrin receptor,
NTBI enters non-hematopoietic cells by other cellular channels in
forms that can possibly damage cells [2]. NTBI is also a catalyst for
the formation of reactive oxygen species, causing oxidative damage
[3]. The anterior pituitary gland is sensitive, in a dose-dependent
fashion, to the effects of iron overload from transfusions [4]. Studies
of human anterior pituitary adenomas showed that gonadotropes
require more iron as compared with other pituitary cell types [5].
Thus, these cells are most affected, resulting in declining synthesis
of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Hypogonadotropic hypogonadism in thalassemia is related not
only to iron toxicity on gonadotrope cells but also to adipose tissue
and leptin. In addition to its effects on carbohydrate and fat me-
tabolism and appetite, leptin also acts on the hypothalamic–
pituitary–gonadal (HPG) axis, indirectly stimulating Kiss1 neurons
in the arcuate nucleus [6]. In normal girls and boys, leptin concen-
trations rise before pubertal transition, followed by an initial increase
of LH and FSH. In normal girls, serum leptin concentrations con-
tinue to rise as pubertal development proceeds due to the effect of
estrogen, while the levels decrease in boys due to the inhibitory effect
of testosterone [7,8]. To our knowledge, several studies have been
conducted on leptin levels in different age groups of thalassemic
patients, and in all of them low leptin levels were observed [9].
Therefore, low circulating leptin may be one of the factors causing
delayed puberty in thalassemic patients.
The direct effect of iron, in particular that of NTBI, on the ovaries
and testes is currently unknown. The ovarian reserve is preserved
in the majority of female thalassemia patients, even in women with
amenorrhea. In males, histological examination of testicular tissues
from autopsies demonstrated testicular interstitial ﬁbrosis with small,
heavily pigmented, undifferentiated seminiferous tubules and an
absence of Leydig cells [10].
Iron deposition in the anterior pituitary gland can be demon-
stratedbeginning in theﬁrst decadeof life, but clinicalmanifestations
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are usually not evident until the onset of puberty. At the earlier stage,
only a diminished gonadotropin reserve with intact gonadotropin
pulse was observed [11]. There may be an asymptomatic phase of
pituitary siderosis before hypogonadism occurs. Later, the gonado-
tropin reserve signiﬁcantly diminishes, with markedly reduced
spontaneous pulsatile gonadotropin activity which may lead to ir-
reversible damage of the HPG axis. However, additional studies
are still required before the natural history can be conclusively
determined.
Hematologic phenotypes were signiﬁcantly associated with
hypogonadotropic hypogonadism.Amajority of patients (86.4%)with
the β0/β0 hematologic phenotype developed hypogonadotropic
hypogonadism, while there was only a 25% occurrence in the
β0/β+ phenotype [12]. High serum ferritin levels of more than
2500 ng/mL during puberty was also found to be a risk factor for
hypogonadism [13], with a 2.75 times greater likelihood of having
hypogonadism compared with patients with serum ferritin levels
less than 1000 ng/mL [14]. Nevertheless, splenectomized individu-
alswho had serum ferritin levels less than 2500 ng/mL also had high
rates of endocrine disorders.
The prevalence and severity of hypogonadism in thalassemia
major varies among studies, depending on the age group studied,
genotype of thalassemia [12,15–17], extent of transfusion, age at
the beginning and type of iron chelation therapy [15,18]. Differ-
ences are also observed between those born before and after the
introduction of iron chelation therapy; desferoxamine was intro-
duced in 1975 as an intramuscular injection and in 1980 as a
subcutaneous route.
Data from 7 Italian hospitals showed that the percentage of pa-
tients affected by hypogonadism was the same among those born
in 1970–1974 and 1975–1979 (64.5% and 56.3%, respectively);
however, it was much lower among those born during 1980–1984
(14.3%) [19]. Data from 29 centers in 2004 with a total of 3817 pa-
tients revealed that hypogonadism in adolescents and adults with
thalassemia major had a prevalence of 38% in females and 43% in
males [20,21]. The widespread heterogeneity in epidemiological data
is also due to differences in clinical characteristics.
Treatment and care of thalassemic patients have beenmuch im-
proved in the last few decades, with treatment modalities such as
transfusion, iron chelation and bone marrow transplantation. The
concept of aggressive blood transfusion in the late 1960s and iron
chelation therapywith desferoxamine, introduced in 1975, improved
overallmedian survival and decreased endocrine disturbances. Bone
marrow transplantation became available later in 1981 as the only
curative treatment.
Clinical manifestations
There are three main clinical presentations of the HPG axis de-
rangement in thalassemiamajor, including delayed puberty, arrested
puberty and hypogonadism. Delayed puberty is deﬁned as the
absence of any pubertal signs by 14 years in boys and 13 years in
girls [20]. Arrested puberty is deﬁned as the absence of further pu-
bertal progression for more than 1 year after puberty has started.
In patients with hypogonadism, spontaneous fertility is possi-
ble in well-chelated and well-transfused patients, but others with
hypogonadotropic hypogonadism may need assisted reproductive
techniques. Gonadal function is usually intact in patients with
hypogonadotropic hypogonadism, indicating that ovulation or sper-
matogenesis can be induced by exogenous gonadotropin therapy.
Hypothyroidism and diabetes mellitus also inﬂuence the outcome
of fertility treatment, and speciﬁc treatments are needed. Origa et al.
studied 58 pregnancies in thalassemia major patients. There were
25 spontaneous pregnancies, 6 in oligomenorrhea patients and
1 in a patient with secondary amenorrhea. The remaining 33
pregnancies were achieved following gonadotropin-induced ovu-
lation [22]. According to data from the Royal Hospital in London,
29 pregnancies in 22 thalassemia major patients occurred during
a 15-year period (1989–2004). Of these 29 pregnancies, 16 fol-
lowed spontaneous ovulation, 12 followed gonadotropin injection
for induction of ovulation, and 1 followed clomiphene therapy [23].
Diagnosis
HPG axis dysfunction can manifest as low estradiol or testos-
terone with low to normal serum LH and FSH as commonly seen
in hypogonadotropic hypogonadism. Low estradiol and testosterone
accompanied with increased serum LH and FSH indicates primary
gonadal failure.
Evaluation of testicular function during childhood is diﬃcult since
serum testosterone, LH, and FSH remain very low until the onset
of puberty. Anti-Müllerian hormone (AMH) is a hormone that is
mainly secreted by the Sertoli cells. Serum AMH level is high during
childhood and declines during puberty. In a study of 28 patients with
thalassemia major in Thailand, 15 in prepuberty, circulating AMH
was not signiﬁcantly different from controls, suggesting normal
Sertoli cell function in patients with thalassemiamajor [24]. However,
serum testosterone levels in pubertal patients were lower than in
controls, which suggested that their testicular function is dimin-
ished, despite a normal pubertal onset. In women, AMH corresponds
well with antral follicle count and can be used to accurately assess
the ovarian reserve, independent of gonadotropin levels. AMH levels
in thalassemia patients are overall normal, signifying that ovarian
reserve is preserved and possibly serving as an important biomarker
for reproduction [25].
The role of pituitary magnetic resonance imaging (MRI) in thal-
assemic patients has been studied in recent years. Hypogonadotropic
hypogonadism is often hard to recognize before puberty because
of the immaturity of the HPG axis [26]. Early detection of pitu-
itary iron overload is important since hypogonadism is not fully
reversible by iron chelation [27]. MRI has been used to predict as-
ymptomatic iron deposition in the heart, liver, pancreas, and pituitary
gland [28–30]. Decreased pituitary volume has been observed, which
may be due to apoptosis of gonadotropic cells, failure of gonado-
tropic cells to grow properly, and also the possibility of suppressed
leptin level. Patients with transfusion iron overload begin to develop
pituitary iron deposition since during the ﬁrst decade of life. However
signiﬁcant pituitary volume loss, using mean and standard devia-
tion for a particular age, is not observed until the second to third
decade of life. Thus, the critical time for MRI surveillance may be
at 10–20 years of age when many patients rapidly accumulate pi-
tuitary iron [26]. For children under the age of 7 years, MRI data
are lacking. Pituitary volume loss is also an independent predictor
of hypogonadism [30], especially a Z-score of pituitary volume lower
than −2.5 [26] or pituitary height less than 4.4 mm [31]. However,
MRI results reveal that many patients with moderate to severe pi-
tuitary iron overload retain normal gland volume, representing an
opportunity for iron chelation treatment and potential improve-
ment in pituitary function [26].
Iron deposition in the anterior pituitary gland can decrease pi-
tuitary MRI signal intensity signiﬁcantly in the T2-weighted image
[30]. MRI signal hypointensity is due to the paramagnetic effect of
iron [15], and serves as a useful tool for early detection of pituitary
iron overload [30]. In a study of 33 patients with homozygous
β-thalassemia, MRI results correlated well with GnRH stimulation
tests, but not the clinical pubertal status of patients [28].
Although liver iron concentration has been considered to be an
excellent marker of total body iron load, no relationship has been
found between liver and pituitary iron deposit using MRI [32,33].
No association betweenMRI parameters of siderosis in the pituitary
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gland and in other solid organs has been demonstrated [33,34]. The
lack of correlation may be due to differences in transferrin recep-
tor concentration, iron kinetics, and the degree of organ inﬂammation
or ﬁbrosis.
Hypogonadism after iron chelation therapy and
bone marrow transplantation
In chronic iron overload, when transferrin is completely satu-
rated,NTBI, the formof iron that causes toxicity, is found in theplasma.
Intensiﬁcationof chelation therapyhasbeenshownto improvecardiac
function, but not in the liver. The mechanism proposed was that
the heart and also endocrine tissue, including the pituitary gland,
take up circulating labile iron species that are non-transferrin-
bound iron, while liver iron uptake is mediated via transferrin.
Chelation therapywith desferoxamine before the age of puberty
has helped patients to attain normal sexual maturation in some
studies but not in others. In a study of 40 patients with transfusion-
dependent thalassemia major, 90% of 19 patients who began
treatmentwithdesferoxaminebefore the ageof 10hadnormal sexual
development comparedwith only 38% of those treated after the age
of 10 [18]. In contrast, another study reported no difference in the
frequency of pubertal maturationwhen iron chelation therapywas
started at the age of 10 or earlier [19]. Serum ferritin levels were
still higher than normal in previous studies, a recent study tar-
geted the achievement of normal ferritin levels. Desferoxamine, in
combinationwith deferiprone, was orally administered to ﬁfty two
thalassemic patients, aged 10–49, until the serum ferritin levelswere
normal; the clearance of liver and heart iron was demonstrated by
MRI. After a period of 5–7 years, 50% of hypogonadalmales achieved
normal testosterone levels and 32% of amenorrheicwomen became
pregnant, either spontaneously or using in vitro fertilization [27].
Withmodernmedications, iron-induced hypogonadismmay be re-
versible with intensive iron chelation regimens.
Two major concerns for hypogonadism in transplanted
thalassemics are iron overload and conditioning regimen. Busulfan
plus cyclophosphamide and cyclosporine used in transplantation
may be responsible for gonadal damage, which was observed pri-
marily in prepubertal girls,whereas the same study foundnoobvious
gonadal damage in boys [35]. Since ovarian failure is common, it is
important to counsel patients on the pros and cons of bonemarrow
transplantation regarding fertility issues. In contrast, patients un-
dergoing conventional treatment usually have hypogonadotropic
hypogonadism, but pregnancy is still possible using hormonal
stimulation.
Despite early successful bonemarrow transplantation, only some
patients reach puberty spontaneously. In a series involving 50
thalassemia patients who received a transplant before puberty (3.6–
14.5 years old), 40% entered puberty normally despite most of them
showing clinical and hormonal evidence of gonadal dysfunction. No
correlation was found between the pubertal stage and age at bone
marrow transplantation [36]. De Sanctis studied 68 thalassemic pa-
tients who had successfully undergone bonemarrow transplantation
during childhood; 34% of females (mean age 16 years) attained pu-
bertal maturation, while 63% of males (mean age 18 years) also
reached puberty [37].
Treatment
Sex steroid or pulsatile GnRH can be utilized to induce puberty
if the HPG axis is functionally intact, especially at an early stage of
hypogonadotropic hypogonadism. Later on, if the HPG axis is irre-
versibly damaged, sex steroid replacement therapy is the only option
to induce puberty. Generally, it is advisable to initiate puberty with
sex steroid replacement therapy by age 13 in women and age 14
in men [38]. Factors such as severity of iron overload, liver disease
and growth hormone deﬁciency should be considered before pu-
bertal induction [20].
Treatment in women
According to the Thalassaemia International Federation recom-
mendations [20], therapy in women may begin with oral ethinyl
estradiol (2.5–5 μg daily) for 6 months, followed by hormonal re-
assessment. If spontaneous puberty does not occur within 6months
after the end of treatment, oral estrogen is reintroduced in gradu-
ally increasing doses (ethinyl estradiol from 5–10 μg daily) for
another 12 months. If patients do not experience breakthrough
uterine bleeding, low-dose estrogen–progesterone hormone re-
placement is the recommended treatment.
Treatment in men
For treatment of delayed puberty in men, intramuscular testos-
terone enantate or cypionate (30–50 mg) are given monthly for
6 months, followed by hormonal reassessment. In patients with
hypogonadotropic hypogonadism, treatment at a dose of 50 mg
monthly can be continued until growth rates wane. The fully vir-
ilizing dose is 75–100 mg of testosterone esters every 10 days,
administered intramuscularly after growth is almost completed
and afterwards. Other preparation of testosterone such as topical
testosterone gel can be used as well.
The risks and beneﬁts of hormone replacement therapy should
be discussed with patients. The high incidence of thromboembolic
event in thalassemia, 1–29% from various studies [39], has led to
the identiﬁcation of a hypercoagulable state in thalassemic patients.
The absence of the spleen can contribute to and increase the risk
of thrombosis in many hematologic diseases. From the treatment
of symptoms of the menopause clinical practice guideline of the En-
docrine Society, randomized controlled trials (RCT) demonstrated
that oral estrogen increases venous thromboembolism (VTE) risk
in women aged 50 to 59 [40]. Observational studies and meta-
analyses suggest that transdermal estrogen therapy does not increase
VTE risk, even in women with thrombophilia. No RCTs were con-
ducted in thalassemic patients; thus, hormonal replacement therapy
in hypogonadal thalassemic patients should be used cautiously,
preferably in transdermal form.
Many factors contribute to the high prevalence of low bone
mineral density, fractures and bone pain in thalassemia patients.
Hypogonadism might be the main determinant of reduced bone
mass, but other causes include ineffective erythropoiesis, alter-
ation in the growth hormone/insulin-like growth factor I axis,
thalassemia genotypes, vitamin D status, iron overload and treat-
ment with iron chelation therapy [41]. The studies of hormonal
replacement in thalassemia patients have yielded inconsistent results.
An improvement in bone mineral density after gonadal hormone
replacement has been reported in some but not all studies [41].
Carmina et al. studied bone mass in 30 adult women, average age
28.5 years, with thalassemia major; 13 of 24 hypogonadal pa-
tients received hormone replacement therapy beginning at an
average age of 15 years, but their bone mass and bone turnover
markers were not different from untreated patients [42]. Anapliotou
et al. followed 27 thalassemia major patients (12 without treat-
ment, 7 on continuous replacement and 8 on on/off schemes
followed by continuous therapy). The regimen comprised either
transdermal estradiol (100 μg) plus medroxyprogesterone for
females, or hCG to produce serum testosterone concentrations within
the normal range for males. Continuous hormone replacement
therapy with transdermal estrogen for females or hCG for respond-
ing males best improved the bone density parameters [43]. Lasco
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et al. studied 40 thalassemia patients, 20 of whom had been re-
ceiving sex hormone replacement therapy for 3 years on average.
Early hormone replacement therapy was able to improve the pattern
of bone loss signiﬁcantly at L2–L4 and the femoral neck. Osteopo-
rosis was only observed at the lumbar spine in treated patients, while
in untreated patients, it also involved the femoral neck [44].
Tanner staging should be performed every 6 months in prepu-
bescent children, as well as annual monitoring for LH and FSH
between 8 and 10 years of age [45]. The ultra-sensitive assays, the
Immunochemiluminometric (ICMA) LH and FSH assays, should be
carried out when testing puberty in children.
Conclusions
Hypogonadotropic hypogonadism resulting from iron deposi-
tion in the pituitary gonadotrope is commonly found in thalassemia
major patients. Early diagnosis and treatment are crucial for normal
pubertal development and to reduce the complications of
hypogonadism.
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